Marinus Pharmaceuticals, Inc. (MRNS)

1.4100 -0.0300 (-2.08%) At close: 04:00PM EDT

Marinus Pharmaceuticals, Inc.

5 Radnor Corporate Center
Suite 500 100 Matsonford Road
Radnor, PA 19087
United States
484 801 4670
https://marinuspharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 165

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Scott N. Braunstein M.D.	CEO, President & Chairman	1.01M	N/A	1963
Mr. Steven E. Pfanstiel C.M.A., M.B.A.	COO, CFO & Treasurer	670.25k	N/A	1973
Dr. Joseph Hulihan M.D.	Chief Medical Officer	665.47k	N/A	1957
Dr. Alex Aimetti Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Sonya Weigle	Senior VP of Investor Relations, Human Resources & Corporate Affairs	N/A	N/A	N/A
Ms. Martha E. Manning Esq., J. D.	Senior VP, General Counsel & Secretary	N/A	N/A	1955
Molly Cameron	Director of Corporate Communications & Investor Relations	N/A	N/A	N/A
Dr. Kimberly A. McCormick Pharm.D.	Chief Regulatory & Quality Assurance Officer	N/A	N/A	N/A
Mr. Thomas J. Lyons	Chief Business Officer	N/A	N/A	N/A
Ms. Christina Shafer	Chief Commercial Officer	N/A	N/A	1977

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.

Corporate Governance

Marinus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.